China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | China Resources Sanjiu Pharmaceutical Co., Ltd. (referred to as "CR Sanjiu") is a large state-owned pharmaceutical listed company mainly engaged in the research and development, production, sales, and related health services of pharmaceutical products. Since its listing, the company has been rated as one of the "Top 100 Jinniu" and "Top 100 Value" listed companies on the Chinese main board multiple times. As of now, China Resources 39 has been included in the Shenzhen Composite Index, CSI 500, MSCI Emerging Markets Index, and FTS Russell. The predecessor of China Resources 39 was the Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies, including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd., initiated the establishment of a joint-stock company; On March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code 000999); In 2008, officially joined China Resources Group; In 2010, the company name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". CR 39's core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a wide range of product coverage and a rich product line. CHC's health consumer goods business covers nearly 10 categories, including colds, skin, gastrointestinal, cough relief, orthopedics, and pediatrics. Its core products occupy a high market share in colds, gastrointestinal, skin, pediatrics, mineral, cough relief, and orthopedic drugs; The prescription drug business focuses on the treatment fields of tumors, cardiovascular and cerebrovascular diseases, digestive system, orthopedics, pediatrics, etc., with multiple products ranking at the forefront of the domestic market. China Resources 39 currently has 23 varieties with annual sales exceeding 100 million yuan, and the "999" brand enjoys high recognition among consumers and the pharmaceutical industry. For many years, China Resources 39 has been continuously listed on the "Most Valuable Chinese Brand List" released by WPP Group; It has continuously ranked top in the comprehensive ranking of non prescription drug enterprises issued by the China Non prescription Drug Association, and 999 Ganmaoling Granules/Capsules has won the first place in the category of cold and cough (traditional Chinese patent medicines and simple preparations) for many years. In addition, China Resources 39 also has up to 10 products at the top of the rankings. CR 39 has always attached great importance to research and development innovation. Its research projects focus on the company's products "Shenfu Injection", "Honghua Injection", "Shenmai Injection", "Xintailin", and "Xuesaitong Soft Capsules (Li Qi Wang)", and have won the National Science and Technology Progress Second Prize four times. Entering the 14th Five Year Plan, China Resources 39 will continue to increase research and development investment, accelerate the construction of innovation systems, and gradually enhance innovation capabilities around the strategic direction. China Resources 39 and Shenzhen Bay Laboratory have launched innovative cooperation to vigorously promote clinical research related to the innovative anti-tumor drug QBH-196 project. At the same time, the establishment and operation of three research institutes for innovative drugs, traditional Chinese medicine, and health drugs have promoted the company to make positive progress in the fields of new product project approval, new product introduction, and product strength enhancement. In 2021, the proportion of R&D investment in CR 39's new products significantly increased. The company has 71 research projects, mainly focusing on strategic areas such as tumors, orthopedics, skin, respiration, and anti infection, and combining innovation and imitation to carry out product layout. Among them, the newly introduced Class 1 innovative traditional Chinese medicine DZQE for improving menopausal symptoms in women is undergoing preclinical preparation work. The research progress of a class 1 small molecule targeted anti-tumor drug QBH-196 is smooth, and phase I clinical trials have been conducted. Class 2 new drug "Mitoxantrone Hydrochloride Injection for Tracing" (trade name: Futashu) has obtained a "Drug Registration Certificate" and is on the market for sale. This product is the first domestically approved tracer product for draining lymph nodes in thyroid surgery areas. Against the backdrop of constantly changing environment in the pharmaceutical industry, China Resources 39 leads "high-quality development" with innovation, adheres to the dual wheel drive of brand+innovation, continuously carries out innovation transformation and upgrading, strengthens brand and channel construction, increases innovation investment, improves operational quality and efficiency, stabilizes industry position, and achieves sustained growth in business performance. In 2021, the company achieved a revenue of 15.32 billion yuan, a year-on-year increase of 12.34%; The net profit attributable to shareholders of the listed company was 2.047 billion yuan, an increase of 28.13% year-on-year. During the 14th Five Year Plan period, China Resources 39 will benchmark against world-class enterprises, improve its business layout, and expand its core business towards self diagnosis and treatment in all fields; Developing business focuses on pipelines, empowering core businesses, and forming a "deeply rooted and leafy" business model. Facing the future, China Resources 39 will always keep in mind its original mission, and under the guidance of the mission of "caring for public health and creating a better life together", move towards the goal of "leading the mass pharmaceutical and health industry" in China; Innovatively utilizing traditional Chinese and Western medical technology, focusing on the innovative research and development of high-quality medical and health products and intelligent manufacturing, serving every member of the Chinese family, and striving to become the first brand of Chinese medical and health. Hand in hand with one heart, walking with love. |
| Headquarter | Shenzhen |
| Establish Date | 4/21/1999 |
| Listed Code | 000999.SZ |
| Listed Date | 3/9/2000 |
| Chairman | Qiu Huawei. |
| CEO | Zhao Bingxiang. |
| Website | www.999.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
